LLOVET J M , KELLEY R K , VILLANUEVA A , et al . Hepatocellular carcinoma [J ] . Nat Rev Dis Primers , 2021 , 7 ( 1 ): 6 . DOI: 10.1038/s41572-020-00240-3 http://doi.org/10.1038/s41572-020-00240-3

MARQUARDT J U , ANDERSEN J B , THORGEIRSSON S S . Functional and genetic deconstruction of the cellular origin in liver cancer [J ] . Nat Rev Cancer , 2015 , 15 ( 11 ): 653 - 667 . DOI: 10.1038/nrc4017 http://doi.org/10.1038/nrc4017

CHEN W , ZHENG R , BAADE P D , et al . Cancer statistics in China, 2015 [J ] . CA Cancer J Clin , 2016 , 66 ( 2 ): 115 - 132 . DOI: 10.3322/caac.21338 http://doi.org/10.3322/caac.21338 http://doi.wiley.com/10.3322/caac.21338 http://doi.wiley.com/10.3322/caac.21338

PEISELER M , SCHWABE R , HAMPE J , et al . Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease-novel insights into cellular communication circuits [J ] . J Hepatol , 2022 , 77 ( 4 ): 1136 - 1160 . DOI: 10.1016/j.jhep.2022.06.012 http://doi.org/10.1016/j.jhep.2022.06.012 https://linkinghub.elsevier.com/retrieve/pii/S0168827822003750 https://linkinghub.elsevier.com/retrieve/pii/S0168827822003750

IOANNOU G N . Epidemiology and risk-stratification of NAFLD-associated HCC [J ] . J Hepatol , 2021 , 75 ( 6 ): 1476 - 1484 . DOI: 10.1016/j.jhep.2021.08.012 http://doi.org/10.1016/j.jhep.2021.08.012

CHEN W , WEN L , BAO Y Y , et al . Gut flora disequilibrium promotes the initiation of liver cancer by modulating tryptophan metabolism and up-regulating SREBP2 [J ] . Proc Natl Acad Sci U S A , 2022 , 119 ( 52 ): e2203894119.

YIP T C , WONG V W , LAI M S , et al . Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss [J ] . J Hepatol , 2023 , 78 ( 3 ): 524 - 533 . DOI: 10.1016/j.jhep.2022.11.020 http://doi.org/10.1016/j.jhep.2022.11.020 https://linkinghub.elsevier.com/retrieve/pii/S0168827822033141 https://linkinghub.elsevier.com/retrieve/pii/S0168827822033141

JOHNSON P , ZHOU Q , DAO D Y , et al . Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma [J ] . Nat Rev Gastroenterol Hepatol , 2022 , 19 ( 10 ): 670 - 681 . DOI: 10.1038/s41575-022-00620-y http://doi.org/10.1038/s41575-022-00620-y

GAO Q , ZENG Q , WANG Z J , et al . Circulating cell-free DNA for cancer early detection [J ] . Innovation (Camb) , 2022 , 3 ( 4 ): 100259 .

YANG X R , LIU R , ZHOU J , et al . Discovery and clinical validation of cost-effective noninvasive early detection of hepatocellular carcinoma (HCC) through circulating tumor DNA (ctDNA) methylation signature [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): 4103 . DOI: 10.1200/JCO.2022.40.16_suppl.4103 http://doi.org/10.1200/JCO.2022.40.16_suppl.4103 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4103 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4103

CHEN L , ABOU-ALFA G K , ZHENG B , et al . Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients [J ] . Cell Res , 2021 , 31 ( 5 ): 589 - 592 . DOI: 10.1038/s41422-020-00457-7 http://doi.org/10.1038/s41422-020-00457-7

FODA Z H , ANNAPRAGADA A V , BOYAPATI K , et al . Detecting liver cancer using cell-free DNA fragmentomes [J ] . Cancer Discov , 2023 , 13 ( 3 ): 616 - 631 . DOI: 10.1158/2159-8290.CD-22-0659 http://doi.org/10.1158/2159-8290.CD-22-0659 https://aacrjournals.org/cancerdiscovery/article/13/3/616/716762/Detecting-Liver-Cancer-Using-Cell-Free-DNA https://aacrjournals.org/cancerdiscovery/article/13/3/616/716762/Detecting-Liver-Cancer-Using-Cell-Free-DNA

ZHANG X Y , WANG Z , TANG W , et al . Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics [J ] . Hepatology , 2022 , 76 ( 2 ): 317 - 329 . DOI: 10.1002/hep.32308 http://doi.org/10.1002/hep.32308 https://journals.lww.com/10.1002/hep.32308 https://journals.lww.com/10.1002/hep.32308

QU C F , WANG Y T , WANG P , et al . Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy [J ] . Proc Natl Acad Sci U S A , 2019 , 116 ( 13 ): 6308 - 6312 . DOI: 10.1073/pnas.1819799116 http://doi.org/10.1073/pnas.1819799116 https://pnas.org/doi/full/10.1073/pnas.1819799116 https://pnas.org/doi/full/10.1073/pnas.1819799116

CAI J B , CHEN L , ZHANG Z , et al . Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma [J ] . Gut , 2019 , 68 ( 12 ): 2195 - 2205 . DOI: 10.1136/gutjnl-2019-318882 http://doi.org/10.1136/gutjnl-2019-318882

FUJIWARA N , KUBOTA N , CROUCHET E , et al . Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease [J ] . Sci Transl Med , 2022 , 14 ( 650 ): eabo4474 . DOI: 10.1126/scitranslmed.abo4474 http://doi.org/10.1126/scitranslmed.abo4474 https://www.science.org/doi/10.1126/scitranslmed.abo4474 https://www.science.org/doi/10.1126/scitranslmed.abo4474

ANDERSON N M , SIMON M C . The tumor microenvironment [J ] . Curr Biol , 2020 , 30 ( 16 ): R921 - R925 . DOI: 10.1016/j.cub.2020.06.081 http://doi.org/10.1016/j.cub.2020.06.081 https://linkinghub.elsevier.com/retrieve/pii/S0960982220309337 https://linkinghub.elsevier.com/retrieve/pii/S0960982220309337

XUE R D , ZHANG Q M , CAO Q , et al . Liver tumour immune microenvironment subtypes and neutrophil heterogeneity [J ] . Nature , 2022 , 612 ( 7938 ): 141 - 147 . DOI: 10.1038/s41586-022-05400-x http://doi.org/10.1038/s41586-022-05400-x

CHEN S L , HUANG C , LIAO G R , et al . Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences [J ] . Gut , 2023 : gutjnl-gu2022-328428[ Online ahead of print ] .

LU Y M , YANG A Q , QUAN C , et al . A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma [J ] . Nat Commun , 2022 , 13 ( 1 ): 4594 . DOI: 10.1038/s41467-022-32283-3 http://doi.org/10.1038/s41467-022-32283-3

GUO L , YI X F , CHEN L , et al . Single-cell DNA sequencing reveals punctuated and gradual clonal evolution in hepatocellular carcinoma [J ] . Gastroenterology , 2022 , 162 ( 1 ): 238 - 252 . DOI: 10.1053/j.gastro.2021.08.052 http://doi.org/10.1053/j.gastro.2021.08.052 https://linkinghub.elsevier.com/retrieve/pii/S0016508521034715 https://linkinghub.elsevier.com/retrieve/pii/S0016508521034715

BURGESS D J . Spatial transcriptomics coming of age [J ] . Nat Rev Genet , 2019 , 20 ( 6 ): 317 . DOI: 10.1038/s41576-019-0129-z http://doi.org/10.1038/s41576-019-0129-z

WU Y C , CHENG Y F , WANG X D , et al . Spatial omics: navigating to the golden era of cancer research [J ] . Clin Transl Med , 2022 , 12 ( 1 ): e696 . DOI: 10.1002/ctm2.696 http://doi.org/10.1002/ctm2.696

WU R , GUO W B , QIU X Y , et al . Comprehensive analysis of spatial architecture in primary liver cancer [J ] . Sci Adv , 2021 , 7 ( 51 ): eabg3750 . DOI: 10.1126/sciadv.abg3750 http://doi.org/10.1126/sciadv.abg3750 https://www.science.org/doi/10.1126/sciadv.abg3750 https://www.science.org/doi/10.1126/sciadv.abg3750

LIU Y , XUN Z Z , MA K , et al . Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy [J ] . J Hepatol , 2023 , 78 ( 4 ): 770 - 782 . DOI: 10.1016/j.jhep.2023.01.011 http://doi.org/10.1016/j.jhep.2023.01.011 https://linkinghub.elsevier.com/retrieve/pii/S0168827823000235 https://linkinghub.elsevier.com/retrieve/pii/S0168827823000235

LI Q , NI Y , ZHANG L R , et al . HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation [J ] . Signal Transduct Target Ther , 2021 , 6 ( 1 ): 76 .

XU W , ZHAO Z Y , AN Q M , et al . Comprehensive comparison of patient-derived xenograft models in Hepatocellular Carcinoma and metastatic Liver Cancer [J ] . Int J Med Sci , 2020 , 17 ( 18 ): 3073 - 3081 . DOI: 10.7150/ijms.46686 http://doi.org/10.7150/ijms.46686

QUINN J J , JONES M G , OKIMOTO R A , et al . Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts [J ] . Science , 2021 , 371 ( 6532 ): eabc1944 . DOI: 10.1126/science.abc1944 http://doi.org/10.1126/science.abc1944 https://www.science.org/doi/10.1126/science.abc1944 https://www.science.org/doi/10.1126/science.abc1944

ZHOU L , YU K H , WONG T L , et al . Lineage tracing and single-cell analysis reveal proliferative Prom1 + tumour-propagating cells and their dynamic cellular transition during liver cancer progression [J ] . Gut , 2022 , 71 ( 8 ): 1656 - 1668 .

YANG D , JONES M G , NARANJO S , et al . Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution [J ] . Cell , 2022 , 185 ( 11 ): 1905 - 1923.e25 . DOI: 10.1016/j.cell.2022.04.015 http://doi.org/10.1016/j.cell.2022.04.015

HE L J , PU W J , LIU X X , et al . Proliferation tracing reveals regional hepatocyte generation in liver homeostasis and repair [J ] . Science , 2021 , 371 ( 6532 ): eabc4346 . DOI: 10.1126/science.abc4346 http://doi.org/10.1126/science.abc4346 https://www.science.org/doi/10.1126/science.abc4346 https://www.science.org/doi/10.1126/science.abc4346

SUN Y F , WU L , ZHONG Y , et al . Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma [J ] . Cell , 2021 , 184 ( 2 ): 404 - 421.e16 . DOI: 10.1016/j.cell.2020.11.041 http://doi.org/10.1016/j.cell.2020.11.041

AGHAYEV T , MAZITOVA A M , FANG J R , et al . IL27 signaling serves as an immunologic checkpoint for innate cytotoxic cells to promote hepatocellular carcinoma [J ] . Cancer Discov , 2022 , 12 ( 8 ): 1960 - 1983 . DOI: 10.1158/2159-8290.CD-20-1628 http://doi.org/10.1158/2159-8290.CD-20-1628 https://aacrjournals.org/cancerdiscovery/article/12/8/1960/707258/IL27-Signaling-Serves-as-an-Immunologic-Checkpoint https://aacrjournals.org/cancerdiscovery/article/12/8/1960/707258/IL27-Signaling-Serves-as-an-Immunologic-Checkpoint

WONG A M , DING X F , WONG A M , et al . Unique molecular characteristics of NAFLD-associated liver cancer accentuate β-catenin/TNFRSF19-mediated immune evasion [J ] . J Hepatol , 2022 , 77 ( 2 ): 410 - 423 . DOI: 10.1016/j.jhep.2022.03.015 http://doi.org/10.1016/j.jhep.2022.03.015 https://linkinghub.elsevier.com/retrieve/pii/S0168827822001842 https://linkinghub.elsevier.com/retrieve/pii/S0168827822001842

WEI C Y , ZHU M X , ZHANG P F , et al . PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma [J ] . J Hepatol , 2022 , 77 ( 1 ): 163 - 176 . DOI: 10.1016/j.jhep.2022.02.019 http://doi.org/10.1016/j.jhep.2022.02.019 https://linkinghub.elsevier.com/retrieve/pii/S016882782200126X https://linkinghub.elsevier.com/retrieve/pii/S016882782200126X

LIU Q X , LI J X , ZHANG W J , et al . Glycogen accumulation and phase separation drives liver tumor initiation [J ] . Cell , 2021 , 184 ( 22 ): 5559 - 5576.e19 . DOI: 10.1016/j.cell.2021.10.001 http://doi.org/10.1016/j.cell.2021.10.001

HU B , YU M C , MA X L , et al . IFNα potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment [J ] . Cancer Discov , 2022 , 12 ( 7 ): 1718 - 1741 . DOI: 10.1158/2159-8290.CD-21-1022 http://doi.org/10.1158/2159-8290.CD-21-1022 https://aacrjournals.org/cancerdiscovery/article/12/7/1718/705192/IFN-Potentiates-Anti-PD-1-Efficacy-by-Remodeling https://aacrjournals.org/cancerdiscovery/article/12/7/1718/705192/IFN-Potentiates-Anti-PD-1-Efficacy-by-Remodeling

NING Z , GUO X , LIU X L , et al . USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma [J ] . Nat Commun , 2022 , 13 ( 1 ): 2187 . DOI: 10.1038/s41467-022-29846-9 http://doi.org/10.1038/s41467-022-29846-9

BERARDI D E , BOCK-HUGHES A , TERRY A R , et al . Lipid droplet turnover at the lysosome inhibits growth of hepatocellular carcinoma in a BNIP3-dependent manner [J ] . Sci Adv , 2022 , 8 ( 41 ): eabo2510 . DOI: 10.1126/sciadv.abo2510 http://doi.org/10.1126/sciadv.abo2510 https://www.science.org/doi/10.1126/sciadv.abo2510 https://www.science.org/doi/10.1126/sciadv.abo2510

SUN R Q , ZHANG Z Y , BAO R X , et al . Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis [J ] . J Hepatol , 2022 , 77 ( 2 ): 453 - 466 . DOI: 10.1016/j.jhep.2022.02.030 http://doi.org/10.1016/j.jhep.2022.02.030

LIU F Z , TIAN T , ZHANG Z , et al . Long non-coding RNA SNHG6 couples cholesterol sensing with mTORC1 activation in hepatocellular carcinoma [J ] . Nat Metab , 2022 , 4 ( 8 ): 1022 - 1040 . DOI: 10.1038/s42255-022-00616-7 http://doi.org/10.1038/s42255-022-00616-7

XU J J , JI L , RUAN Y L , et al . UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma [J ] . Signal Transduct Target Ther , 2021 , 6 ( 1 ): 190 .

GAO C , WANG S W , LU J C , et al . KSR2-14-3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma [J ] . Biomark Res , 2022 , 10 ( 1 ): 25 . DOI: 10.1186/s40364-022-00361-9 http://doi.org/10.1186/s40364-022-00361-9

JIN H J , SHI Y P , LV Y Y , et al . EGFR activation limits the response of liver cancer to lenvatinib [J ] . Nature , 2021 , 595 ( 7869 ): 730 - 734 . DOI: 10.1038/s41586-021-03741-7 http://doi.org/10.1038/s41586-021-03741-7

HU B Y , ZOU T T , QIN W , et al . Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma [J ] . Cancer Res , 2022 , 82 ( 20 ): 3845 - 3857 . DOI: 10.1158/0008-5472.CAN-21-4140 http://doi.org/10.1158/0008-5472.CAN-21-4140

PAN J M , ZHANG M , DONG L Q , et al . Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma [J ] . Autophagy , 2023 , 19 ( 4 ): 1184 - 1198 . DOI: 10.1080/15548627.2022.2117893 http://doi.org/10.1080/15548627.2022.2117893 https://www.tandfonline.com/doi/full/10.1080/15548627.2022.2117893 https://www.tandfonline.com/doi/full/10.1080/15548627.2022.2117893

MOK E H K , LEUNG C O N , ZHOU L , et al . Caspase-3-induced activation of SREBP2 drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma [J ] . Cancer Res , 2022 , 82 ( 17 ): 3102 - 3115 .

CALDERARO J , SERAPHIN T P , LUEDDE T , et al . Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma [J ] . J Hepatol , 2022 , 76 ( 6 ): 1348 - 1361 . DOI: 10.1016/j.jhep.2022.01.014 http://doi.org/10.1016/j.jhep.2022.01.014

LIU B E , ZENG Q Y , HUANG J B , et al . IVIM using convolutional neural networks predicts microvascular invasion in HCC [J ] . Eur Radiol , 2022 , 32 ( 10 ): 7185 - 7195 . DOI: 10.1007/s00330-022-08927-9 http://doi.org/10.1007/s00330-022-08927-9

GAO R T , ZHAO S , AISHANJIANG K , et al . Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data [J ] . J Hematol Oncol , 2021 , 14 ( 1 ): 154 . DOI: 10.1186/s13045-021-01167-2 http://doi.org/10.1186/s13045-021-01167-2

SHI J Y , WANG X D , DING G Y , et al . Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning [J ] . Gut , 2021 , 70 ( 5 ): 951 - 961 . DOI: 10.1136/gutjnl-2020-320930 http://doi.org/10.1136/gutjnl-2020-320930 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-320930 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-320930

REIG M , FORNER A , RIMOLA J , et al . BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update [J ] . J Hepatol , 2022 , 76 ( 3 ): 681 - 693 . DOI: 10.1016/j.jhep.2021.11.018 http://doi.org/10.1016/j.jhep.2021.11.018 https://linkinghub.elsevier.com/retrieve/pii/S0168827821022236 https://linkinghub.elsevier.com/retrieve/pii/S0168827821022236

中华人民共和国国家卫生健康委员会医政医管局 . 原发性肝癌诊疗指南(2022年版) [J ] . 中华肝脏病杂志 , 2022 ( 4 ): 367 - 388 .

Medical Administration Bureau of the National Health Commission of the People's Republic of China . Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition) [J ] . Chin J Hepatol , 2022 ( 4 ): 367 - 388 .

VOGEL A , MEYER T , SAPISOCHIN G , et al . Hepatocellular carcinoma [J ] . Lancet , 2022 , 400 ( 10360 ): 1345 - 1362 . DOI: 10.1016/S0140-6736(22)01200-4 http://doi.org/10.1016/S0140-6736(22)01200-4

DI BENEDETTO F , MAGISTRI P , DI SANDRO S , et al . Safety and efficacy of robotic vs open liver resection for hepatocellular carcinoma [J ] . JAMA Surg , 2023 , 158 ( 1 ): 46 - 54 . DOI: 10.1001/jamasurg.2022.5697 http://doi.org/10.1001/jamasurg.2022.5697 https://jamanetwork.com/journals/jamasurgery/fullarticle/2798993 https://jamanetwork.com/journals/jamasurgery/fullarticle/2798993

ZHU P , LIAO W , ZHANG W G , et al . A prospective study using propensity score matching to compare long-term survival outcomes after robotic-assisted, laparoscopic, or open liver resection for patients with BCLC stage 0-a hepatocellular carcinoma [J ] . Ann Surg , 2023 , 277 ( 1 ): e103 - e111 . DOI: 10.1097/SLA.0000000000005380 http://doi.org/10.1097/SLA.0000000000005380 https://journals.lww.com/10.1097/SLA.0000000000005380 https://journals.lww.com/10.1097/SLA.0000000000005380

陈昭硕 , 林科灿 , 刘景丰 . 三维可视化技术在原发性肝癌外科手术中的应用 [J ] . 临床肝胆病杂志 , 2022 , 38 ( 3 ): 505 - 509 .

CHEN Z S , LIN K C , LIU J F . Application of three-dimensional visualization in surgical operation for primary liver cancer [J ] . J Clin Hepatol , 2022 , 38 ( 3 ): 505 - 509 .

TABRIZIAN P , HOLZNER M L , MEHTA N , et al . Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma [J ] . JAMA Surg , 2022 , 157 ( 9 ): 779 - 788 . DOI: 10.1001/jamasurg.2022.2800 http://doi.org/10.1001/jamasurg.2022.2800

FAMULARO S , DONADON M , CIPRIANI F , et al . Hepatectomy versus sorafenib in advanced nonmetastatic hepatocellular carcinoma: a real-life multicentric weighted comparison [J ] . Ann Surg , 2022 , 275 ( 4 ): 743 - 752 . DOI: 10.1097/SLA.0000000000005373 http://doi.org/10.1097/SLA.0000000000005373

PENG Z W , FAN W Z , ZHU B W , et al . Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase Ⅲ, randomized clinical trial (LAUNCH) [J ] . J Clin Oncol , 2023 , 41 ( 1 ): 117 - 127 .

LI Q J , HE M K , CHEN H W , et al . Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase Ⅲ trial [J ] . J Clin Oncol , 2022 , 40 ( 2 ): 150 - 160 .

WANG Z , LIU M , ZHANG D Z , et al . Microwave ablation versus laparoscopic resection as first-line therapy for solitary 3-5-cm HCC [J ] . Hepatology , 2022 , 76 ( 1 ): 66 - 77 . DOI: 10.1002/hep.32323 http://doi.org/10.1002/hep.32323 https://journals.lww.com/10.1002/hep.32323 https://journals.lww.com/10.1002/hep.32323

LIU K W , ZHENG H , SUI X Z , et al . Microwave ablation versus surgical resection for subcapsular hepatocellular carcinoma: a propensity score-matched study of long-term therapeutic outcomes [J ] . Eur Radiol , 2023 , 33 ( 3 ): 1938 - 1948 . DOI: 10.1007/s00330-022-09135-1 http://doi.org/10.1007/s00330-022-09135-1

YU J , CHENG Z G , HAN Z Y , et al . Period-dependent survival benefit of percutaneous microwave ablation for hepatocellular carcinoma: a 12-year real-world, multicentric experience [J ] . Liver Cancer , 2022 , 11 ( 4 ): 341 - 353 . DOI: 10.1159/000522134 http://doi.org/10.1159/000522134

LEE S , KANG T W , SONG K D , et al . Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation [J ] . Ann Surg , 2021 , 273 ( 3 ): 564 - 571 . DOI: 10.1097/SLA.0000000000003268 http://doi.org/10.1097/SLA.0000000000003268 https://journals.lww.com/10.1097/SLA.0000000000003268 https://journals.lww.com/10.1097/SLA.0000000000003268

XIA Y , LI J , LIU G H , et al . Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial [J ] . JAMA Oncol , 2020 , 6 ( 2 ): 255 - 263 . DOI: 10.1001/jamaoncol.2019.4477 http://doi.org/10.1001/jamaoncol.2019.4477 https://jamanetwork.com/journals/jamaoncology/fullarticle/2756225 https://jamanetwork.com/journals/jamaoncology/fullarticle/2756225

CHEN S L , ZENG X Z , SU T H , et al . Combinatory local ablation and immunotherapies for hepatocellular carcinoma: rationale, efficacy, and perspective [J ] . Front Immunol , 2022 , 13 : 1033000 . DOI: 10.3389/fimmu.2022.1033000 http://doi.org/10.3389/fimmu.2022.1033000 https://www.frontiersin.org/articles/10.3389/fimmu.2022.1033000/full https://www.frontiersin.org/articles/10.3389/fimmu.2022.1033000/full

CHEN B , WU J X , CHENG S H , et al . Phase 2 study of adjuvant radiotherapy following narrow-margin hepatectomy in patients with HCC [J ] . Hepatology , 2021 , 74 ( 5 ): 2595 - 2604 . DOI: 10.1002/hep.31993 http://doi.org/10.1002/hep.31993 https://journals.lww.com/10.1002/hep.31993 https://journals.lww.com/10.1002/hep.31993

SU K , GU T , XU K , et al . Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study [J ] . Hepatol Int , 2022 , 16 ( 4 ): 858 - 867 . DOI: 10.1007/s12072-022-10339-2 http://doi.org/10.1007/s12072-022-10339-2

DAWSON L A , WINTER K , KNOX J , et al . NRG/RTOG 1112: randomized phase Ⅲ study of sorafenib vs stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC) (NCT01730937) [J ] . Int J Radiat Oncol Biol Physics , 2022 , 114 ( 5 ): 1057 . DOI: 10.1016/j.ijrobp.2022.09.002 http://doi.org/10.1016/j.ijrobp.2022.09.002 https://linkinghub.elsevier.com/retrieve/pii/S0360301622032606 https://linkinghub.elsevier.com/retrieve/pii/S0360301622032606

SUN Y K , ZHANG W , BI X Y , et al . Systemic therapy for hepatocellular carcinoma: Chinese consensus-based interdisciplinary expert statements [J ] . Liver Cancer , 2022 , 11 ( 3 ): 192 - 208 . DOI: 10.1159/000521596 http://doi.org/10.1159/000521596

FINN R S . LBA34-primary results from the phase Ⅲ LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) [C ] . ESMO Congress , 2022 : S808 -S869.

QIN S , CHAN L S , GU S , et al . LBA35 Camrelizumab (C) plus rivoceranib (R) vs sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase Ⅲtrial [J ] . Ann Oncol , 2022 , 33 : S1401 - S1402 .

QIN S K , CHEN Z D , FANG W J , et al . Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase Ⅲtrial [J ] . J Clin Oncol , 2023 , 41 ( 7 ): 1434 - 1443 . DOI: 10.1200/JCO.22.00620 http://doi.org/10.1200/JCO.22.00620 https://ascopubs.org/doi/10.1200/JCO.22.00620 https://ascopubs.org/doi/10.1200/JCO.22.00620

SHAO G L , BAI Y X , YUAN X L , et al . Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): a randomised, multicentre, double-blind study [J ] . EClinicalMedicine , 2022 , 54 : 101679 . DOI: 10.1016/j.eclinm.2022.101679 http://doi.org/10.1016/j.eclinm.2022.101679 https://linkinghub.elsevier.com/retrieve/pii/S2589537022004096 https://linkinghub.elsevier.com/retrieve/pii/S2589537022004096

KUDO M . Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma [J ] . Hepatobiliary Surg Nutr , 2022 , 11 ( 4 ): 592 - 596 . DOI: 10.21037/hbsn http://doi.org/10.21037/hbsn http://hbsn.amegroups.com http://hbsn.amegroups.com

XING B , DA X , ZHANG Y , et al . A phase Ⅱ study combining KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma (HCC): updated efficacy and safety results [J ] . JCO , 2022 , 40 ( 16_suppl ): 4115 . DOI: 10.1200/JCO.2022.40.16_suppl.4115 http://doi.org/10.1200/JCO.2022.40.16_suppl.4115 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4115 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4115

SUN H C , ZHOU J , WANG Z , et al . Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition) [J ] . Hepatobiliary Surg Nutr , 2022 , 11 ( 2 ): 227 - 252 . DOI: 10.21037/hbsn http://doi.org/10.21037/hbsn http://hbsn.amegroups.com http://hbsn.amegroups.com

SUN H , ZHU X , GAO Q , et al . Sintilimab combined with bevacizumab biosimilar as a conversion therapy in potentially resectable intermediate stage hepatocellular carcinoma (HCC): a phase Ⅱ trial [J ] . Ann Oncol , 2022 , 33 : S867 - S868 .

SUN H C , SHEN F , LIU L X , et al . TALENTop: a multicenter, randomized study evaluating the efficacy and safety of hepatic resection for selected hepatocellular carcinoma with macrovascular invasion after initial atezolizumab plus bevacizumab treatment [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): TPS4175 . DOI: 10.1200/JCO.2022.40.16_suppl.TPS4175 http://doi.org/10.1200/JCO.2022.40.16_suppl.TPS4175 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS4175 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS4175

SUN H , SHEN F , BAI X , et al . Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: a pre-specified analysis of the TALENTop study [J ] . Ann Oncol , 2022 , 33 ( 1_suppl ): 1470 .

LIU D . Hepatic artery infusion chemotherapy (HAIC) combined with sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC): a prospective, single-arm phase Ⅱ trial [C ] . 2022 ASCO Annual Meeting I. American Society of Clinical Oncology (ASCO) . 2022 .

FENG X B , ZHANG L , NIU H M , et al . Selective internal radiation therapy with yttrium-90 resin microspheres followed by anatomical hepatectomy: a potential curative strategy in advanced hepatocellular carcinoma [J ] . Asia Pac J Clin Oncol , 2023 [ Online ahead of print ] .

CAI Z X , SU X P , QIU L M , et al . Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion [J ] . Mol Cancer , 2021 , 20 ( 1 ): 164 . DOI: 10.1186/s12943-021-01467-8 http://doi.org/10.1186/s12943-021-01467-8

PENG S , CHEN S L , HU W , et al . Combination neoantigen-based dendritic cell vaccination and adoptive T-cell transfer induces antitumor responses against recurrence of hepatocellular carcinoma [J ] . Cancer Immunol Res , 2022 , 10 ( 6 ): 728 - 744 . DOI: 10.1158/2326-6066.CIR-21-0931 http://doi.org/10.1158/2326-6066.CIR-21-0931 https://aacrjournals.org/cancerimmunolres/article/10/6/728/699035/Combination-Neoantigen-Based-Dendritic-Cell https://aacrjournals.org/cancerimmunolres/article/10/6/728/699035/Combination-Neoantigen-Based-Dendritic-Cell

LLOVET J M , MONTAL R , SIA D , et al . Molecular therapies and precision medicine for hepatocellular carcinoma [J ] . Nat Rev Clin Oncol , 2018 , 15 ( 10 ): 599 - 616 . DOI: 10.1038/s41571-018-0073-4 http://doi.org/10.1038/s41571-018-0073-4

ZHU A X , FINN R S , EDELINE J , et al . Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial [J ] . Lancet Oncol , 2018 , 19 ( 7 ): 940 - 952 . DOI: S1470-2045(18)30351-6 http://doi.org/S1470-2045(18)30351-6

SHI J W , LIU J W , TU X X , et al . Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy [J ] . J Immunother Cancer , 2022 , 10 ( 1 ): e003133 . DOI: 10.1136/jitc-2021-003133 http://doi.org/10.1136/jitc-2021-003133 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-003133 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-003133

PINATO D J , MARRON T U , MISHRA-KALYANI P S , et al . Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice [J ] . Eur J Cancer , 2021 , 157 : 140 - 152 . DOI: 10.1016/j.ejca.2021.08.020 http://doi.org/10.1016/j.ejca.2021.08.020

WANG J , HUANG A , WANG Y P , et al . Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma [J ] . Ann Transl Med , 2020 , 8 ( 5 ): 237 . DOI: 10.21037/atm.2019.12.154 http://doi.org/10.21037/atm.2019.12.154

SUN Y F , WU L , LIU S P , et al . Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma [J ] . Nat Commun , 2021 , 12 ( 1 ): 4091 . DOI: 10.1038/s41467-021-24386-0 http://doi.org/10.1038/s41467-021-24386-0

RICCIUTI B , WANG X N , ALESSI J V , et al . Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels [J ] . JAMA Oncol , 2022 , 8 ( 8 ): 1160 - 1168 . DOI: 10.1001/jamaoncol.2022.1981 http://doi.org/10.1001/jamaoncol.2022.1981

LIN Z F , QIN L X , CHEN J H . Biomarkers for response to immunotherapy in hepatobiliary malignancies [J ] . Hepatobiliary Pancreat Dis Int , 2022 , 21 ( 5 ): 413 - 419 . DOI: 10.1016/j.hbpd.2022.08.002 http://doi.org/10.1016/j.hbpd.2022.08.002 https://linkinghub.elsevier.com/retrieve/pii/S1499387222001886 https://linkinghub.elsevier.com/retrieve/pii/S1499387222001886

LARKIN J , CHIARION-SILENI V , GONZALEZ R , et al . Five-year survival with combined nivolumab and ipilimumab in advanced melanoma [J ] . N Engl J Med , 2019 , 381 ( 16 ): 1535 - 1546 . DOI: 10.1056/NEJMoa1910836 http://doi.org/10.1056/NEJMoa1910836 http://www.nejm.org/doi/10.1056/NEJMoa1910836 http://www.nejm.org/doi/10.1056/NEJMoa1910836